Ranok Therapeutics (hangzhou) Co., Ltd.
Clinical trials sponsored by Ranok Therapeutics (hangzhou) Co., Ltd., explained in plain language.
-
New drug targets 'Undruggable' mutation in deadly pancreatic cancer
Disease control Recruiting nowThis study is testing an experimental drug called RNK08954 for people with advanced pancreatic cancer that has spread and has a specific genetic change called KRAS G12D. The main goals are to see if the drug is safe and if it can help slow or stop the cancer's growth. It is for a…
Phase: PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New pill targets 'Undruggable' cancer mutation in first human tests
Disease control Recruiting nowThis is the first study in people to test a new oral medication called RNK08954. It aims to find a safe and effective dose for adults with advanced solid tumors that have a specific genetic change called a KRAS G12D mutation. The study will also see if the drug can help control t…
Phase: PHASE1, PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC